Royal Philips
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Royal Philips (PHG) | 27.97B | 26.34 | 2.20 | 3.44% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 15.3% below Morningstar's fair value estimate.
Fair value
Koninklijke Philips NV earns a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 11% discount to our quantitative fair value estimate of $33.00 per share, which is reinforced by this estimate's low uncertainty rating.
The firm's profitability bolsters our quantitative valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's enterprise value to free cash flow ratio of 17.5 falls in the bottom 40% compared with global peers. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.
Conversely, the firm's lack of growth is potentially concerning. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's EPS 5-year growth of 2.3%, for example, falls in the bottom 40% compared with peers globally. On a relative basis, EPS growth has lagged over the last five years, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's wide quantitative moat rating suggests a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Royal Philips discussion 0 comments